Neuromuscular Disorders
Literature Review
Neurologists publish consensus statement on stridor in MSA
The statement provides guidance on the diagnosis, prognosis, and treatment of stridor in patients with MSA, as well as indicating areas for future...
From the Journals
Viral cause of acute flaccid myelitis eludes detection
Acute flaccid myelitis shows a viral etiology but analysis of specimens from affected individuals fails to identify a single viral cause.
Conference Coverage
Coming soon!
Literature Review
Can a novel steroidal anti-inflammatory drug benefit patients with Duchenne muscular dystrophy?
Vamorolone may reduce “safety concerns typically seen with traditional glucocorticoids,” researchers said.
From the Journals
Peripheral nervous system events have lasting impact on SLE patients
Findings from one of the largest-ever cohort studies on PNS manifestations in SLE patients may “provide a benchmark for the assessment of future...
Latest News
NIH launches 5-year, $10 million study on acute flaccid myelitis
Researchers at the University of Alabama at Birmingham will lead the study, which aims to examine the natural history, incidence, and risk factors...
From the Journals
Study refines ALS risk among first-degree relatives of patients with disease
Heritability was high, even in the absence of known genetic factors.
From the Journals
Novel genetic therapy reduces key protein in Huntington’s disease
Intrathecal therapy was associated with dose-dependent reductions in mutant huntingtin protein, but clinical change will require further study.
Conference Coverage
Mutant huntingtin and neurofilament light are potential biomarkers in Huntington’s disease
PHILADELPHIA – The biomarkers successfully distinguish between healthy controls, patients with premanifest disease,...
Conference Coverage
Can an antisense oligonucleotide benefit patients with SOD1-ALS?
PHILADELPHIA – In patients with amyotrophic lateral sclerosis caused by mutations in the SOD1 gene, an investigational treatment reduced SOD1...
FDA/CDC
Ruzurgi approved for Lambert-Eaton myasthenic syndrome in patients under age 17
The approval is the first for a LEMS treatment specifically for pediatric patients.